Piramal Pharma share price gained 3.87 per cent at Rs 252.05 a piece on the BSE in Thursday’s intraday trade. This came after Piramal Pharma’s division Piramal Critical Care (PCC) announced the US launch of Chlorpromazine Hydrochloride Injection which will be offered in 25mg/1mL and 50mg/2 mL vials .
Chlorpromazine Hydrochloride Injection is a medication primarily used to treat a range of psychiatric disorders, including schizophrenia and other psychotic conditions such as paranoia (delusions and intense feelings of worry or nervousness), mania (excessive activity and energy), anxiety, agitation, and impulsive behavior that may be dangerous.
PCC has introduced Chlorpromazine Hydrochloride, marking another addition to its growing portfolio of generic injectables. This launch follows the introduction of Edaravone IV Infusion in 2024. In 2023, PCC further expanded its portfolio with the launches of Pantoprazole Sodium for Injection, USP, and Doxycycline for Injection, USP, underscoring its commitment to providing a comprehensive range of critical care products, the company said in a statement.
